Home › Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal
 

Keywords :   


Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal

2015-12-17 17:08:44| Biotech - Topix.net

The current consensus forecast for fourth quarter HCV sales is $2.81 billion. In the third quarter, U.S. HCV sales had totaled $3.23 billion.

Tags: sales deal tracking digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
More »